Works matching DE "EMTRICITABINE"
Results: 399
HIV post-exposure prophylaxis in the Emergency Department: a perspective from Singapore.
- Published in:
- Proceedings of Singapore Healthcare, 2019, v. 28, n. 3, p. 167, doi. 10.1177/2010105819841391
- By:
- Publication type:
- Article
Bictegravir/emtricitabine/tenofovir Alafenamide for the Treatment of People Living with HIV.
- Published in:
- 2022
- By:
- Publication type:
- Interview
Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults.
- Published in:
- MMWR: Morbidity & Mortality Weekly Report, 2012, v. 61, n. 31, p. 586
- By:
- Publication type:
- Article
Electrochemical Studies of Anti‐HIV Drug Emtricitabine: Oxidative Determination and Improved Antimicrobial Activity.
- Published in:
- ChemElectroChem, 2018, v. 5, n. 24, p. 3926, doi. 10.1002/celc.201801228
- By:
- Publication type:
- Article
ERUPTIVE PIGMENTED PATCHES IN A PATIENT WITH HIV INFECTION UNDER HAART.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH).
- Published in:
- Infectious Disease Reports, 2023, v. 15, n. 6, p. 766, doi. 10.3390/idr15060069
- By:
- Publication type:
- Article
HIV Prevention in Clinical Care Settings.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 4, p. 390, doi. 10.1001/jama.2014.7999
- By:
- Publication type:
- Article
How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities?
- Published in:
- 2024
- By:
- Publication type:
- Letter
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
- Published in:
- PLoS ONE, 2020, v. 15, n. 1, p. 1, doi. 10.1371/journal.pone.0224875
- By:
- Publication type:
- Article
Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies.
- Published in:
- PLoS ONE, 2019, v. 14, n. 11, p. 1, doi. 10.1371/journal.pone.0225146
- By:
- Publication type:
- Article
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 3, p. 696, doi. 10.1093/infdis/jiae211
- By:
- Publication type:
- Article
Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Real world community-based HIV Rapid Start Antiretroviral with B/F/TAF versus prior models of antiretroviral therapy start – the RoCHaCHa study, a pilot study.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00631-6
- By:
- Publication type:
- Article
Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00627-2
- By:
- Publication type:
- Article
Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00616-5
- By:
- Publication type:
- Article
Angiolipoma associated with antiretroviral switch therapy: a case report.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00620-9
- By:
- Publication type:
- Article
Initiating HIV antiretroviral therapy: Criteria, evidence, and controversy.
- Published in:
- JAAPA: Journal of the American Academy of Physician Assistants (Haymarket Media, Inc.), 2011, v. 24, n. 2, p. 26, doi. 10.1097/01720610-201102000-00005
- By:
- Publication type:
- Article
Age: HIV knows no boundary.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
AIDS: Drugs that prevent HIV infection.
- Published in:
- Nature, 2011, v. 469, n. 7330, p. 306, doi. 10.1038/469306a
- By:
- Publication type:
- Article
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 24, p. 7759, doi. 10.3390/jcm12247759
- By:
- Publication type:
- Article
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, n. 4, p. 479, doi. 10.1111/bcpt.13161
- By:
- Publication type:
- Article
Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up.
- Published in:
- Biomedicines, 2024, v. 12, n. 11, p. 2620, doi. 10.3390/biomedicines12112620
- By:
- Publication type:
- Article
SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System.
- Published in:
- Biomedicines, 2021, v. 9, n. 8, p. 996, doi. 10.3390/biomedicines9080996
- By:
- Publication type:
- Article
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 4, p. 583, doi. 10.3390/jpm13040583
- By:
- Publication type:
- Article
Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
- Published in:
- HIV Medicine, 2024, v. 25, n. 9, p. 1030, doi. 10.1111/hiv.13659
- By:
- Publication type:
- Article
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'.
- Published in:
- HIV Medicine, 2024, v. 25, n. 5, p. 600, doi. 10.1111/hiv.13608
- By:
- Publication type:
- Article
Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real‐life experience from a French cohort (2019–2023).
- Published in:
- HIV Medicine, 2024, v. 25, n. 2, p. 299, doi. 10.1111/hiv.13562
- By:
- Publication type:
- Article
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
- Published in:
- HIV Medicine, 2023, v. 24, n. 11, p. 1126, doi. 10.1111/hiv.13542
- By:
- Publication type:
- Article
Treatment‐emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
- Published in:
- HIV Medicine, 2023, v. 24, n. 11, p. 1137, doi. 10.1111/hiv.13520
- By:
- Publication type:
- Article
Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia.
- Published in:
- HIV Medicine, 2023, v. 24, n. 10, p. 1035, doi. 10.1111/hiv.13545
- By:
- Publication type:
- Article
Immune response to ART initiation in advanced HIV infection.
- Published in:
- HIV Medicine, 2023, v. 24, n. 6, p. 716, doi. 10.1111/hiv.13467
- By:
- Publication type:
- Article
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
- Published in:
- HIV Medicine, 2023, v. 24, n. 3, p. 290, doi. 10.1111/hiv.13386
- By:
- Publication type:
- Article
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment‐naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
- Published in:
- HIV Medicine, 2023, v. 24, n. 3, p. 279, doi. 10.1111/hiv.13377
- By:
- Publication type:
- Article
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
- Published in:
- HIV Medicine, 2023, v. 24, n. 3, p. 361, doi. 10.1111/hiv.13376
- By:
- Publication type:
- Article
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age.
- Published in:
- HIV Medicine, 2023, v. 24, n. 1, p. 27, doi. 10.1111/hiv.13319
- By:
- Publication type:
- Article
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022.
- Published in:
- HIV Medicine, 2022, v. 23, p. 3, doi. 10.1111/hiv.13446
- By:
- Publication type:
- Article
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
- Published in:
- HIV Medicine, 2022, v. 23, n. 8, p. 849, doi. 10.1111/hiv.13268
- By:
- Publication type:
- Article
Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
- Published in:
- HIV Medicine, 2022, v. 23, n. 4, p. 362, doi. 10.1111/hiv.13215
- By:
- Publication type:
- Article
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation.
- Published in:
- HIV Medicine, 2020, v. 21, n. 5, p. 309, doi. 10.1111/hiv.12829
- By:
- Publication type:
- Article
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
- Published in:
- HIV Medicine, 2020, v. 21, n. 3, p. 198, doi. 10.1111/hiv.12819
- By:
- Publication type:
- Article
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study
- Published in:
- HIV Medicine, 2019, v. 20, n. 2, p. 164, doi. 10.1111/hiv.12688
- By:
- Publication type:
- Article
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials.
- Published in:
- HIV Medicine, 2018, v. 19, n. 10, p. 724, doi. 10.1111/hiv.12664
- By:
- Publication type:
- Article
Comparison of 48‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis.
- Published in:
- HIV Medicine, 2018, v. 19, n. 8, p. 559, doi. 10.1111/hiv.12643
- By:
- Publication type:
- Article
Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.
- Published in:
- HIV Medicine, 2018, v. 19, n. 7, p. 497, doi. 10.1111/hiv.12619
- By:
- Publication type:
- Article
Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
- Published in:
- HIV Medicine, 2017, v. 18, n. 8, p. 537, doi. 10.1111/hiv.12488
- By:
- Publication type:
- Article
An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition.
- Published in:
- HIV Medicine, 2017, v. 18, n. 5, p. 342, doi. 10.1111/hiv.12435
- By:
- Publication type:
- Article
Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands ( ATHENA) cohort.
- Published in:
- HIV Medicine, 2016, v. 17, n. 8, p. 571, doi. 10.1111/hiv.12355
- By:
- Publication type:
- Article
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 132, doi. 10.1111/hiv.12183
- By:
- Publication type:
- Article